Sudbø Jon
Det norske radiumhospital, Avdeling for onkologi, Fagområde stråleterapi, 0310 Oslo.
Tidsskr Nor Laegeforen. 2003 May 29;123(11):1518-21.
Morbidity and mortality from oral cancer is still considerable, and has not improved significantly over the last four or five decades. Early preventive intervention in persons at high risk may improve treatment results.
This review is based on our previously published data and by searches in the Medline and PubMed databases, using the following terms as key words: "oral premalignancies", "oral leukoplakia", "tumour progression", "genomic instability", "aneuploidy", "prognosis", "head and neck cancer", and "chemoprevention".
Chemoprevention requires the early and reliable identification of persons at high risk of cancer. Retinoids have a clinically documented effect towards head-and-neck cancer, but are associated with unacceptable side-effects. Coxibs and inhibitors of epidermal growth factor receptors are candidate agents for chemoprevention of oral cancer.
It is now possible to identify persons at high risk of developing oral cancer who may benefit from chemopreventive use of coxibs or inhibitors of epidermal growth factor receptors.
口腔癌的发病率和死亡率仍然很高，在过去四五十年间并未显著改善。对高危人群进行早期预防性干预可能会改善治疗效果。
本综述基于我们之前发表的数据，并通过检索Medline和PubMed数据库，使用以下术语作为关键词：“口腔癌前病变”、“口腔白斑”、“肿瘤进展”、“基因组不稳定”、“非整倍体”、“预后”、“头颈癌”和“化学预防”。
化学预防需要早期且可靠地识别癌症高危人群。维甲酸对头颈癌有临床记录的疗效，但伴有难以接受的副作用。环氧化酶-2抑制剂（Coxibs）和表皮生长因子受体抑制剂是口腔癌化学预防的候选药物。
现在有可能识别出可能从环氧化酶-2抑制剂或表皮生长因子受体抑制剂的化学预防使用中获益的口腔癌高危人群。
Zotero 插件